Paper Details

  1. Home
  2. Paper Details

Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML.

Author: Al-FarehYousef, BaldusClaudia D, BaumannLukas, BehringerDirk, BornhäuserMartin, BrechtArne, BuskeSebastian, CrysandtMartina, FranseckyLars, GeerThomas, GörnerMartin, HanounMaher, HeldGerhard, HopferOlaf, JaramilloSonia, KaufmannMartin, KayserSabine, KieserMeinhard, KratzmannMarkus, KrauseStefan, KrisamJohannes, Le CornetLucian, Müller-TidowCarsten, NiemannDirk, PlatzbeckerUwe, RankAndreas, RölligChristoph, SauerTim, Schaefer-EckartKerstin, SchlenkRichard F, SchliemannChristoph, SchubertJörg, ServeHubert, TeichmannLino, TrappeRalf-Ulrich

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Overall survival remains poor in older patients with acute myeloid leukemia (AML), but recent studies have shown that adding gemtuzumab ozogamicin (GO) or glasdegib to intensive induction therapy improves survival.
Paper Details　
Original Abstract of the Article :
Overall survival remains poor in older patients with acute myeloid leukemia (AML) with less than 10% being alive after 5 years. In recent studies, a significant improvement in event-free, relapse-free and overall survival was shown by adding gemtuzumab ozogamicin (GO), a humanized antibody-drug conj...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564967/

データ提供：米国国立医学図書館（NLM）

Combating Acute Myeloid Leukemia: A New Approach to Treatment

Acute myeloid leukemia (AML), a type of cancer that affects the blood and bone marrow, is a challenging condition that can be as aggressive as a desert sandstorm. This research investigates a new treatment strategy for AML, aiming to improve outcomes for patients. The study examines the potential of combining two medications, gemtuzumab ozogamicin and glasdegib, to effectively target AML cells.

Targeting AML Cells: A Quest for Better Outcomes

The research highlights the potential of a new combination therapy for AML, offering hope for improved outcomes. This approach is comparable to a desert traveler finding a hidden spring, providing a source of healing and relief. The study emphasizes the importance of ongoing research and clinical trials in the fight against AML.

Navigating the Challenges of Acute Myeloid Leukemia

This research underscores the importance of finding innovative treatments for AML. It's a journey of discovery, much like a desert explorer seeking a path to a hidden oasis. The study provides valuable insights into the potential of new therapies, offering hope for a brighter future for AML patients.

Dr.Camel's Conclusion

This research represents a promising advancement in the treatment of AML. It's a journey of hope, much like a desert explorer venturing into uncharted territory. I, Dr. Camel, believe that this study will pave the way for more effective treatments, leading to better outcomes for AML patients.
Date :
  1. Date Completed 2021-11-05
  2. Date Revised 2022-04-28
Further Info :

Pubmed ID

34732236

DOI: Digital Object Identifier

PMC8564967

Related Literature

Article Analysis
・Effects of glasdegib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.